PSEN1 and Alzheimer disease: Under the conditions used for the mutant APP/PS1 5xFAD model preparation, we did not observe any evident impact of the mTOR inhibitor rapamycin, consistent with existing mTOR dysregulation of LTP in AD model mouse preparations (Ma et al., 2010), shown to be rescued by upregulation of mTOR.